- Home
- SVRE vs CVKD Comparison
SVRE vs CVKD Comparison
Compare SVRE & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRE
- CVKD
- Stock Information
- Founded
- SVRE 2014
- CVKD 2022
- Country
- SVRE Israel
- CVKD United States
- Employees
- SVRE N/A
- CVKD N/A
- Industry
- SVRE
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- SVRE
- CVKD Health Care
- Exchange
- SVRE Nasdaq
- CVKD Nasdaq
- Market Cap
- SVRE 883.2K
- CVKD 29.5M
- IPO Year
- SVRE 2022
- CVKD 2023
- Fundamental
- Price
- SVRE $2.35
- CVKD $12.71
- Analyst Decision
- SVRE
- CVKD Strong Buy
- Analyst Count
- SVRE 0
- CVKD 1
- Target Price
- SVRE N/A
- CVKD $32.00
- AVG Volume (30 Days)
- SVRE 5.2M
- CVKD 35.8K
- Earning Date
- SVRE 08-26-2025
- CVKD 08-06-2025
- Dividend Yield
- SVRE N/A
- CVKD N/A
- EPS Growth
- SVRE N/A
- CVKD N/A
- EPS
- SVRE N/A
- CVKD N/A
- Revenue
- SVRE $462,071.00
- CVKD N/A
- Revenue This Year
- SVRE $458.76
- CVKD N/A
- Revenue Next Year
- SVRE $106.57
- CVKD N/A
- P/E Ratio
- SVRE N/A
- CVKD N/A
- Revenue Growth
- SVRE N/A
- CVKD N/A
- 52 Week Low
- SVRE $1.93
- CVKD $5.70
- 52 Week High
- SVRE $325.36
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- SVRE 43.19
- CVKD 49.98
- Support Level
- SVRE $1.93
- CVKD $11.00
- Resistance Level
- SVRE $3.39
- CVKD $13.56
- Average True Range (ATR)
- SVRE 0.59
- CVKD 1.15
- MACD
- SVRE 0.10
- CVKD 0.25
- Stochastic Oscillator
- SVRE 13.83
- CVKD 80.97
About SVRE SaverOne 2014 Ltd.
Saverone 2014 Ltd provides driver protection solutions. The company develops and deploys ADAS technologies for transportation safety and driver assistance. The company's product restricts the driver from surfing, communicating, and receiving alerts while driving. The company has developed a system that provides a solution to the problem of distracted driving caused by cell phone use, which endangers the driver, passengers, other drivers on the road and pedestrians. Geographially, it operates in Israel and Europe, out of which it derives maximum revenue from Israel.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.